clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ives DV et al. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. 1995 AIDS pmid:7755914
Holmberg SD and Moorman AC Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. 2001 AIDS pmid:11504998
Chaisson RE et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. 1997 AIDS pmid:9147422
Heald AE et al. Taste and smell complaints in HIV-infected patients. 1998 AIDS pmid:9764787
Macías J et al. Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. 1997 AIDS pmid:9030376
Preston SL et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. 1998 AIDS pmid:9468380
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Fichtenbaum CJ et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. 2000 AIDS pmid:11153670
High-dose clarithromycin should be avoided. 1996 AIDS Alert pmid:11363723
Physician's aggressive preventive therapy differs. 1995 AIDS Alert pmid:11362774
New drug applications sought. 1995 AIDS Alert pmid:11362777
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925
Clarithromycin for MAC. 1995 AIDS Patient Care pmid:11361361
Rosales CM et al. AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. 2002 AIDS Patient Care STDS pmid:12542930
Mah Ming JB and Gill MJ Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. 2003 AIDS Patient Care STDS pmid:12816614
Monno R et al. Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. 2001 AIDS Patient Care STDS pmid:11788074
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Desimone JA et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. 2003 AIDS Patient Care STDS pmid:14746655
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. 1996 AIDS Patient Care STDS pmid:11361534
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. 1996 AIDS Patient Care STDS pmid:11361575
Clarithromycin and MAC. 1996 AIDS Patient Care STDS pmid:11361673
Different clarithromycin doses affect mortality. 1997 AIDS Patient Care STDS pmid:11361754
Aboulafia DM Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. 2003 AIDS Read pmid:14524324
Kahlon SS et al. Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. 2008 AIDS Read pmid:18975441
Chu J et al. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. 2011 AIDS Res Ther pmid:21388558
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Wong WM et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. 2003 Aliment. Pharmacol. Ther. pmid:12622764
Fischbach L and Evans EL Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. 2007 Aliment. Pharmacol. Ther. pmid:17635369
Logan RP et al. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. 1995 Aliment. Pharmacol. Ther. pmid:8527618
Bruley Des Varannes S et al. There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. 2001 Aliment. Pharmacol. Ther. pmid:11472320
Masaoka T et al. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. 2004 Aliment. Pharmacol. Ther. pmid:15298608
Kondo Y et al. Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. 2004 Aliment. Pharmacol. Ther. pmid:15298609
Gschwantler M et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. 1999 Aliment. Pharmacol. Ther. pmid:10468682
Chiba N et al. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. 2004 Aliment. Pharmacol. Ther. pmid:14984382
Di Mario F et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 2006 Aliment. Pharmacol. Ther. pmid:16611285
Madisch A et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. 2006 Aliment. Pharmacol. Ther. pmid:16441467
Molina-Infante J et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. 2015 Aliment. Pharmacol. Ther. pmid:25776067
Azuma T et al. Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. 2000 Aliment. Pharmacol. Ther. pmid:10807427
Talley NJ et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9678811
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Ricciardiello L et al. Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. 1998 Aliment. Pharmacol. Ther. pmid:9678812
Kashimura H et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10215732
Vcev A et al. Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. 2000 Aliment. Pharmacol. Ther. pmid:10632647
Laine L et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9354200
Rinaldi V et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. 1997 Aliment. Pharmacol. Ther. pmid:9354202
Peterson WL et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. 1996 Aliment. Pharmacol. Ther. pmid:8791947
Gisbert JP et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. 2012 Aliment. Pharmacol. Ther. pmid:22372560
Harris AW et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. 1996 Aliment. Pharmacol. Ther. pmid:8971302
Moshkowitz M et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. 1996 Aliment. Pharmacol. Ther. pmid:8971304
Graham DY et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. 2003 Aliment. Pharmacol. Ther. pmid:12755836